Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer

Ali Osman Kaya1, Suleyman Buyukberber1, Faysal Dane2, Abdurrahman Isikdogan3, Basak Oven Ustaalioglu4, Ugur Coskun1, Perran Fulden Yumuk2, Gamze Gokoz Dogu5, Nuriye Yildirim Ozdemir6, Alper Sevinc7, Mahmut Gumus4, Metin Ozkan4, Ramazan Yildiz1, Banu Ozturk1, Emel Yaman1, and Mustafa Benedeki1, for the Anatolian Society of Medical Oncology (ASMO)

1Gazi University Faculty of Medicine, Department of Medical Oncology, Ankara; 2Marmara University Faculty of Medicine, Department of Medical Oncology, Istanbul; 3Dicle University Faculty of Medicine, Department of Medical Oncology, Diyarbakir; 4Kartal Lutfi Kirdar Education and Research Hospital, Department of Medical Oncology, Istanbul; 5Erciyes University Faculty of Medicine, Department of Medical Oncology, Kayseri; 6Numune Education and Research Hospital, Department of Medical Oncology, Ankara; 7Gaziantepe University Faculty of Medicine, Department of Medical Oncology, Gaziantepe, Turkey

ABSTRACT


Patients and methods. Between October 2004 and July 2008, 186 patients with metastatic non-small cell lung cancer treated with first-line cisplatin plus docetaxel were retrospectively evaluated in 7 centers. The chemotherapy schedule consisted of cisplatin, 75 mg/m² iv infusion, and docetaxel, 75 mg/m² iv infusion on day 1, every 3 weeks.

Results. Median age was 56 years (range, 28-75). Eighteen patients (9.7%) were females and 168 (90.3%) were males, with a median ECOG performance status of 1 (range, 0-2). A total of 833 cycles of chemotherapy was administered (median, 4 cycles; range, 1-6). Two patients (1.1%) achieved clinical complete response, 77 patients (41.4%) partial response, and 66 patients (35.5%) stable disease. Median time to disease progression was 6 months (95% CI, 5.54-6.46). Median overall survival was 14.6 months (95% CI, 11.47-17.73). One- and 2-year overall survival was 55.2% and 19.7%, respectively. The most common grade 3-4 hematological toxicities were neutropenia (n = 32, 17.2%) and anemia (n = 4, 2.2%).

Conclusions. The cisplatin plus docetaxel combination was effective and safe in the first-line treatment of patients with metastatic non-small cell lung cancer. Free full text available at www.tumorionline.it

Key words: cisplatin, docetaxel, metastatic non-small cell lung cancer.

Correspondence to: Prof Suleyman Buyukberber, Gazi University Faculty of Medicine, Department of Medical Oncology, Besirler, Ankara, 06500, Turkey.
Tel +90-312-2025830; fax +90-312-2158710; e-mail buyukberber@gazi.edu.tr

Received November 25, 2008; accepted December 18, 2009.